Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05654779 | CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid… | Phase 1 | terminated | Dec 16, 2022 | Institute of Hematology & Blood Diseases Hospital, China | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT05316116 | Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) | Early Phase 1 | terminated | Apr 7, 2022 | H. Lee Moffitt Cancer Center and Research Institute | lack of efficacy/futility | Efficacy / futility |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in…(topMIND) | Phase 1 / Phase 2 | terminated | Mar 22, 2021 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Mar 6, 2015 | National Cancer Institute (NCI) | Other - Adverse Events | Safety / toxicity |
| NCT03926624 | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in… | Phase 3 | terminated | Apr 24, 2019 | Delta-Fly Pharma, Inc. | The data met the protocol-specified criteria for futility of the investigational treatment. | Efficacy / futility |
| NCT04230265 | Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic… | Phase 1 | terminated | Jan 18, 2020 | AvenCell Europe GmbH | business decision by sponsor | Sponsor / business decision |
| NCT05181904 | Gastric Content Ultrasound Monitoring Prior to Extubation in Critically Ill Children(GastrExtub) | — | terminated | Jan 10, 2022 | Hospices Civils de Lyon | Patient enrollment difficulties | Enrollment / accrual |
| NCT04150029 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit…(STIMULUS-AML1) | Phase 2 | terminated | Nov 4, 2019 | Novartis Pharmaceuticals | Novartis made a decision to early terminate the sabatolimab clinical development program, including… | Other (stated, no rule matched) |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With…(STIMULUS-MDS2) | Phase 3 | terminated | Feb 12, 2020 | Novartis Pharmaceuticals | In December 2023, Novartis decided to terminate the sabatolimab clinical development program early… | Safety / toxicity |
| NCT04049383 | CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL(CAR-20/19-T) | Phase 1 | terminated | Aug 8, 2019 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT05799079 | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients… | Phase 2 | terminated | Apr 5, 2023 | Sanjay Mohan | Study was terminated early due to lack of accrual and loss of funding. | Enrollment / accrual |
| NCT03760523 | Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Nov 30, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Toxicity -Two DLT events occurred | Safety / toxicity |
| NCT04163718 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 15, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Drug no longer available | Other (stated, no rule matched) |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With… | Phase 1 / Phase 2 | withdrawn | Jul 17, 2025 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT04240002 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and… | Phase 1 / Phase 2 | terminated | Jan 27, 2020 | Astellas Pharma Global Development, Inc. | The study was terminated due to enrollment challenges. | Enrollment / accrual |
| NCT03708003 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | Phase 2 | terminated | Oct 16, 2018 | Swiss Cancer Institute | The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has… | Funding |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | terminated | Jan 18, 2020 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT03055286 | Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Phase 1 / Phase 2 | terminated | Feb 16, 2017 | JW Pharmaceutical | business/strategic reason | Sponsor / business decision |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic… | Phase 1 / Phase 2 | terminated | Apr 8, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03698552 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic… | Phase 1 / Phase 2 | terminated | Oct 9, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT01570868 | Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | Phase 2 | terminated | Apr 4, 2012 | M.D. Anderson Cancer Center | Closed due to slow accrual | Enrollment / accrual |
| NCT05361057 | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive… | Phase 2 | terminated | May 4, 2022 | Institute of Hematology & Blood Diseases Hospital, China | The research center has conducted a more comprehensive study. | Other (stated, no rule matched) |
| NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent… | Phase 2 | terminated | Jul 19, 2022 | M.D. Anderson Cancer Center | The sponsor requested termination due to internal reprioritization of resources. | Other (stated, no rule matched) |
| NCT06709131 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory…(CT0991) | Phase 1 | suspended | Nov 29, 2024 | He Huang | Product manufacturing process improvement | Drug supply |
| NCT06454409 | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients… | Phase 1 | suspended | Jun 12, 2024 | City of Hope Medical Center | resources | Other (stated, no rule matched) |
| NCT07004816 | The Mutation Profile and Prognosis in AML With IDH1/2 Mutation | — | terminated | Jun 4, 2025 | Institute of Hematology & Blood Diseases Hospital, China | Adapted the plan | Other (stated, no rule matched) |
| NCT04937166 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological… | Phase 1 | terminated | Jun 23, 2021 | Kahr Medical | Slow enrolment | Enrollment / accrual |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid… | Phase 1 / Phase 2 | terminated | May 5, 2021 | M.D. Anderson Cancer Center | The study terminated early because the company was longer providing the investigational product. | Sponsor / business decision |
| NCT04511130 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant(ARTEMIS) | Phase 2 | terminated | Aug 13, 2020 | Marker Therapeutics, Inc. | Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long… | Drug supply |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jul 29, 2019 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT06940570 | Methadone as an Alternative Treatment for Children Underdoing HSCT(MATCH) | Phase 3 | suspended | Apr 23, 2025 | University of Texas Southwestern Medical Center | Study is closed with the IRB due to no funding. May resume once funding is obtained. | Funding |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual… | Phase 1 / Phase 2 | terminated | Sep 9, 2020 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04623216 | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of… | Phase 1 / Phase 2 | terminated | Nov 10, 2020 | Novartis Pharmaceuticals | Study was stopped following a strategic decision from the Sponsor. It was not based on any safety… | Safety / toxicity |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | Phase 1 | withdrawn | Dec 11, 2014 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn by PI | Other (stated, no rule matched) |
| NCT04678336 | CD123 Redirected T Cells for AML in Pediatric Subjects | Phase 1 | terminated | Dec 21, 2020 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | — | terminated | Feb 23, 2024 | Young Adult Survivors United | Sponsoring organization no longer desired to recruit/maintain registry | Enrollment / accrual |
| NCT03940352 | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia… | Phase 1 | terminated | May 7, 2019 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | Phase 1 | terminated | Jan 27, 2020 | Novartis Pharmaceuticals | Business, strategic, and development considerations and not due to any safety concerns | Safety / toxicity |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological… | Phase 1 | terminated | Jan 8, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With… | Phase 1 / Phase 2 | terminated | Aug 6, 2020 | Takeda | Phase 1 enrollment was terminated due to dose-limiting toxicities, thus the study was terminated by… | Safety / toxicity |
| NCT01258933 | Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy | Phase 2 | terminated | Dec 13, 2010 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03948529 | RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell…(REGALIA) | Phase 2 | terminated | May 14, 2019 | University Hospital, Lille | inclusions difficulties. | Other (stated, no rule matched) |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded…(ACHIEVE) | Phase 2 | terminated | May 3, 2022 | TC Biopharm | The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January… | Other (stated, no rule matched) |
| NCT05168202 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and… | Phase 1 | terminated | Dec 23, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT05961839 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic… | Phase 1 | terminated | Jul 27, 2023 | Schrödinger, Inc. | Company decision | Sponsor / business decision |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With…(ISAKIDS) | Phase 2 | terminated | Mar 4, 2019 | Sanofi | Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due… | Safety / toxicity |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid…(5) | Phase 2 | terminated | May 8, 2015 | Institut Curie | No objective response was observed at the first step. The treatment was considered ineffective,… | Other (stated, no rule matched) |
| NCT03564678 | Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab… | Phase 2 | terminated | Jun 21, 2018 | M.D. Anderson Cancer Center | PI Request. Slow accrual and lack of clinical interest | Enrollment / accrual |
| NCT06639958 | A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at… | N/A | suspended | Oct 15, 2024 | Children's Oncology Group | All potential pilot phase pts have been enrolled. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 11, 2026source: clinicaltrials